Skip to main content
Clinical Trials/NCT04606589
NCT04606589
Completed
Early Phase 1

Feasibility Study Evaluating the Efficacy of a Wireless Vital Signs Monitor for Critically Ill Newborns in Kenya

Neopenda, PBC1 site in 1 country167 target enrollmentFebruary 1, 2021

Overview

Phase
Early Phase 1
Intervention
Not specified
Conditions
Newborn Morbidity
Sponsor
Neopenda, PBC
Enrollment
167
Locations
1
Primary Endpoint
In-hospital newborn mortality
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The neoGuard device is a 4-in-1 wearable vital signs monitor designed to continuously measure temperature, pulse rate (PR), respiratory rate (RR) and blood oxygen saturation (SpO2) in newborns. In this study, researchers will evaluate the feasibility of the neoGuard device at two rural health facilities in Western Kenya and assess the preliminary efficacy of the technology in improving health outcomes for newborns.

This is a pre/post intervention study. The standard-of-care arm (n=223) will be enrolled between 20 Oct - 20 Nov, 2020 and the neoGuard intervention arm (n=223) will be enrolled between 1 - 31 Dec, 2020.

Registry
clinicaltrials.gov
Start Date
February 1, 2021
End Date
May 30, 2021
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age \<28 days
  • Admitted to the neonatal intensive care unit
  • Weight at birth/admission ≥2000 g
  • Low-to-moderate disease severity as determined by the Signs of Inflammation in Children that Kill (SICK) score card (SICK score ≤2.4 at admission is eligible)
  • Parent/guardian willing to provide informed consent for their newborn to participate in study

Exclusion Criteria

  • Age \>28 days
  • Has a condition that impairs them from wearing the device, such as hydrocephaly.
  • Weight at birth \<2000 g
  • Very severe disease status (SICK score \>2.4 at admission)

Outcomes

Primary Outcomes

In-hospital newborn mortality

Time Frame: From date of admission to date of discharge or referral or death, up to 28 days

Proportion of deaths that occur during hospital stay.

Secondary Outcomes

  • Complication rate(From date of admission to date of discharge or referral or death, up to 28 days)
  • Length of stay in hospital(From date of admission to date of discharge or referral or death, up to 28 days)

Study Sites (1)

Loading locations...

Similar Trials